Chugai and Biofourmis Collaborating to Develop Digital Solution For Objective Assessment of Pain

23. July 2020

Chugai Biofourmis partnership — Biofourmis’ Biovitals platform collects and interprets vast amounts of population metadata and compares it to real-time patient physiological signals to provide a clearer picture of chronic patients and their disease trajectory (Image: Biofourmis)

Chugai Pharmaceutical, one of Japan’s leading research-based pharmaceutical companies and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis. Read more Wearables In Combination With Digital Technology Offers Huge Opportunities For Non-Invasive Pain Management Endometriosis is the repeated proliferation […]

To access this post, you must purchase Free Subscription, Premium Subscription or Premium Subscription (6 months, special rate).

Patients Expect Their Wearables To Be Durable, Comfortable, And More

Harvard, Stanford and U Mich Researchers Propose AI Framework That Delivers…

Solos Health Announces Early Fever Detection Technology ‘FeverGuard’

How Technology Is Helping Employers Reopen Their Businesses After COVID-19 Lockdown

From Pregnant Mothers To Pets, Japan Is Making Swift Progress In…

Chugai and Biofourmis Collaborating to Develop Digital Solution For Objective Assessment of Pain

Patients Expect Their Wearables To Be Durable, Comfortable, And More